RP
MED icon

Rowlandmiller & Partners’s Medifast MED Stock Holding History

Rowlandmiller & Partners’s Portfolio MED Stock Details MED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,976
Closed -$114K – 183
2024
Q1 		$114K Sell
2,976
-3,733
-56% -$181K 0.02% 172
2023
Q4 		$451K Sell
6,709
-1,378
-17% -$96K 0.1% 99
2023
Q3 		$605K Buy
8,087
+2,250
+39% +$200K 0.15% 88
2023
Q2 		$538K Buy
5,837
+600
+11% +$53.4K 0.13% 96
2023
Q1 		$543K Sell
5,237
-5
-0.1% -$554 0.13% 96
2022
Q4 		$603K Buy
5,242
+35
+0.7% +$4.08K 0.15% 91
2022
Q3 		$564K Sell
5,207
-125
-2% -$17.9K 0.15% 91
2022
Q2 		$962K Buy
5,332
+355
+7% +$63.5K 0.25% 67
2022
Q1 		$850K Buy
4,977
+195
+4% +$36.8K 0.2% 79
2021
Q4 		$1M Buy
+4,782
New +$988K 0.22% 75
2021
Q3 		– Sell
-4,557
Closed -$1.29M – 171
2021
Q2 		$1.29M Buy
4,557
+1,859
+69% +$504K 0.32% 62
2021
Q1 		$571K Buy
+2,698
New +$646K 0.15% 90

Other funds holding MED

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Rowlandmiller & Partners's MED Position: Q2 2024 in Review

Rowlandmiller & Partners sold out of Medifast (MED) in Q2 2024, closing a stake of 2,976 shares — an estimated $114K sold.

Rowlandmiller & Partners first reported a position in MED in Q1 2021 and held it in 12 quarters. The position peaked at $1.29M in Q2 2021. 158 funds tracked by Wall St. Rank hold MED as of Q2 2024.

  • Rowlandmiller & Partners reported no remaining Medifast position as of Q2 2024 after selling out during the quarter.
  • Rowlandmiller & Partners sold 2,976 Medifast shares in Q2 2024, an estimated $114K.
  • Rowlandmiller & Partners first reported a position in Medifast in Q1 2021 and held it in 12 quarters.
  • Rowlandmiller & Partners's Medifast position peaked at $1.29M in Q2 2021.
  • 158 funds tracked by Wall St. Rank held Medifast as of Q2 2024.

Based on Rowlandmiller & Partners's 13F filing for Q2 2024, filed 29 Jul 2024.